This site is fictional demo content. It is not real news or affiliated with any real organization. Do not treat it as fact or professional advice.

NextPaper Logo
nextpaper.ccCYBER CHRONICLE
RSS
EN中文

Full article

FULL TEXT

View this issue
BriefMEDTECH

Gene Editing Safety Monitoring System GeneSafe Launches: Real-Time Tracking of CRISPR Off-Target Effects

Swiss genetic testing company Genespire's GeneSafe system can continuously monitor patients for off-target mutations after gene editing therapy, with detection sensitivity reaching the single-cell level.

Gene Editing Safety Monitoring System GeneSafe Launches: Real-Time Tracking of CRISPR Off-Target Effects

Swiss genetic testing company Genespire released GeneSafe on January 7, a system for continuously monitoring off-target effects after gene editing therapy. GeneSafe uses liquid biopsy technology to detect circulating DNA fragments in the blood, identifying unintended mutations that CRISPR editing may introduce at the single-cell level.

The system performs blood tests on patients every two weeks. AI algorithms compare the results against the patient's pre-edit baseline genome, flagging any anomalous mutations and assessing their potential risk.

GeneSafe has received EMA approval and is priced at 1,200 euros per test. Genespire says the system will initially be used for safety monitoring of approved gene editing therapies, including CRISPR treatments for sickle cell disease and beta-thalassemia.